Reading the tape
NASDAQ: DWTX
Dogwood Therapeutics, Inc.
Healthcare · Biotechnology
Data caution
Per-share valuation inputs need verification
Event dated Dec 31, 2025Market-derived shares outstanding and recent statement shares differ materially. Per-share ratios and valuation outputs may be unreliable until the share base is verified. This sometimes appears with ADRs or provider share-count gaps.
Market Cap
$2.75M
52w High
$9.50
52w Low
$1.28
P/E
-0.61
Volume
43.94K
Outstanding Shares
1.91M
Price vs Fundamentals
Why The Stock Is Moving
Likely fundamental deteriorationModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -69.92%FCF (TTM): -77.67%
What changed
The stock fell 69.92% over the last year. Free cash flow declined 77.67% over the trailing twelve months.
What the market seems to be pricing
The market appears to be responding to weaker operating momentum rather than only rerating the stock.
What would invalidate this read
Free cash flow fell 77.67% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response.
CEOGregory Duncan
SectorHealthcare
IndustryBiotechnology
Employees12
IPO dateDec 17, 2020
Valuation
Forward P/E—
EV/EBITDA-1.00
Enterprise value$27.83M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-45.74%▼138.08%vs FY2024
Analyst consensus
RatingBuy
Target price—
1
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.22 · Revenue est —
View